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To the Editor:
Malignant pleural mesothelioma 
(MPM) is a particularly aggressive pri-
mary tumor associated with exposure 
to asbestos and characterized by a high 
mortality.1
To date, there are no curative ther-
apies available for MPM, so that clini-
cal studies to evaluate many targeted 
therapies are currently underway.2 MET 
is a proto-oncogene located on chromo-
some 7q21-31 that encodes a receptor 
tyrosine kinase playing a role in both 
normal development and tumorigen-
esis.3 Hepatocyte growth factor is the 
only known ligand of MET receptor. 
Hepatocyte growth factor/MET signal-
ing cascade leads to a variety of cellu-
lar functions, including increased cell 
proliferation, survival, apoptosis, cell 
motility, angiogenesis, migration, and 
invasion. Physiologically, MET is in a 
quiescent signaling state in adult tis-
sues. This signaling may be aberrantly 
activated by the amplification of MET 
gene, which may also lead to MET pro-
tein overexpression. Furthermore, it 
was reported that amplification of MET 
in non–small-cell lung cancer is one of 
the reason for resistance to anti–tyro-
sine kinase inhibitor targeted therapies.4
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207REG2014), and the informed writ-
ten consent was obtained from the 
patient. A pleural biopsy of a 70-year-
old nonsmoker Caucasian male, previ-
ously exposed to asbestos for a long 
period of time, was analyzed in our 
laboratory for diagnosis in March 
2010.
Histology and immunohisto-
chemistry (IHC) were carried out on 
4-µm thick tissue sections from the 
biopsy samples embedded in paraffin 
blocks. Histological slides, stained with 
hematoxylin–eosin, showed a malig-
nant proliferation of epithelioid cells 
(Fig. 1A). IHC reaction showed strong 
reactivity for calretinin and cytokera-
tin 5/6, associated with negative reac-
tivity for carcino-embryonic antigen, 
epithelial membrane antigen, estrogen 
receptor and progesterone receptor (not 
shown). A diagnosis of epithelioid MPM 
was made. The patient was treated with 
six cycles of cisplatin plus pemetrexed 
and died in November 2010.
In a retrospective study, we ana-
lyzed MET by using fluorescence in 
situ hybridization and IHC (Fig. 1). 
The patient had amplification (approxi-
mately eight MET signals on >70% of 
cells; MET/CEP7 ratio = 4.0; Fig. 1C) 
associated with overexpression (cyto-
plasm level and membrane variable 
staining from low to moderate expres-
sion; Fig. 1E).
To our knowledge, this is the first 
report showing that MET gene may be 
amplified in MPM. MET amplification 
leading to MET receptor overexpression 
has been previously described in some 
solid malignancies (e.g., gastric can-
cer, non–small-cell lung cancer, breast 
cancer, and colon carcinoma) in which 
it identifies a subset of cancers poten-
tially able to respond to MET inhibi-
tors.3 Thus, also our MPM patient could 
be candidate for anti-MET therapies. 
Moreover, because MET gene ampli-
fication caused resistance to anti–epi-
dermal growth factor receptor tyrosine 
kinase inhibitor therapies,4 it might 
be relevant to select patients who may 
benefit from epidermal growth factor 
receptor inhibitors.
However, further studies are 
needed to determine the incidence 
of aberrations of MET in MPM and 
whether they have a real relevance 
for biological treatments in this 
malignancy.
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